Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
FR0012333284
Mon, 22.01.2024
ABIVAX
Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months
Induction data read-out expected Q1 2025 from the pivotal Phase 3 ABTECT program evaluating obefazimod in moderately to severely active ulcerative colitis (UC)
Formal process evaluating oral and injectable combination therapy candidates with obefazimod in UC h [ … ]
Thu, 04.01.2024
ABIVAX
Abivax 2024 Financial Communication Calendar
PARIS, France, January 4, 2024, 8:30 a.m. CET – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chro [ … ]
Tue, 21.11.2023
ABIVAX
Abivax announces the resumption of its liquidity contract
Paris, France, November 21, 2023 – 8:30 a.m. CET – Abivax SA (Euronext Paris and Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in pati [ … ]
Tue, 14.11.2023
ABIVAX
Abivax to participate in the Piper Sandler 35th Annual Healthcare Conference
PARIS, France, November 14, 2023, 2:00 p.m. CET – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the imm [ … ]
Tue, 24.10.2023
ABIVAX
Abivax announces Closing of its Initial Public Offering on the Nasdaq Global Market
PARIS, France, October 24, 2023 – 10:05 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to mod [ … ]
Fri, 20.10.2023
ABIVAX
Abivax announces trading resumption of its ordinary shares on Euronext Paris
PARIS, France, October 20, 2023 – 03:45 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate t [ … ]
Fri, 20.10.2023
ABIVAX
Abivax announces the pricing of its Initial Public Offering on the Nasdaq Global Market
PARIS, France, October 20, 2023 – 3:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to [ … ]
Fri, 20.10.2023
ABIVAX
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
PARIS, France, October 20, 2023 – 08:45 a.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modula [ … ]
Thu, 19.10.2023
ABIVAX
Abivax announces the filing of an amended registration statement, including an estimated initial public offering price range
PARIS, France, October 18, 2023 – 11:55 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the bo [ … ]
Mon, 16.10.2023
ABIVAX
Abivax announces the start of the roadshow for its proposed global offering and proposed Nasdaq listing
PARIS, France, October 16, 2023 – 05:40 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulato [ … ]